ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQUIS GROWTH MARKET

APPLICANT NAME:

Blackpoint Biotech PLC

APPLICANT REGISTERED OFFICE, PRINCIPLE PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:

48-49 Chancery Lane, C/O Keystone Law, London, England, WC2A 1JF

8

DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE):

• Michael William Balfour, Non-Executive Chairman
• David Manuel Martinez, Chief Executive Officer
• Alexander James Robert Stormont Wakeford, Chief Financial Officer
• Dr Michael Barry Mayne, Chief Product Officer 

APPLICANT SECTOR:

Healthcare

DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:

Blackpoint Biotech PLC is a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing.

NAME OF AQUIS CORPORATE ADVISER:

First Sentinel Corporate Finance Limited

NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:

12,187,179 Ordinary Shares of £0.005 each

SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):

15.12%

SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT’S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:

TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC:

N/A

THE EXPECTED ADMISSION DATE:

20 July 2023

WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION:

In respect of an update to a prior application announcement, the date of the original announcement should also be disclosed as follows:

UPDATE TO A PRIOR APPLICATION ANNOUNCEMENT RELEASED ON:

N/A